CN111050780A - 脑活素的用途 - Google Patents
脑活素的用途 Download PDFInfo
- Publication number
- CN111050780A CN111050780A CN201880055542.5A CN201880055542A CN111050780A CN 111050780 A CN111050780 A CN 111050780A CN 201880055542 A CN201880055542 A CN 201880055542A CN 111050780 A CN111050780 A CN 111050780A
- Authority
- CN
- China
- Prior art keywords
- cerebrol
- cadasil
- use according
- treated
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000011282 treatment Methods 0.000 claims description 16
- 239000012141 concentrate Substances 0.000 claims description 15
- 230000035772 mutation Effects 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 238000001802 infusion Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 101150103623 NOTCH3 gene Proteins 0.000 claims description 4
- 239000012895 dilution Substances 0.000 claims description 4
- 238000010790 dilution Methods 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 208000010482 CADASIL Diseases 0.000 claims 8
- 208000033221 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 claims 8
- 208000033935 Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy Diseases 0.000 claims 8
- 208000016886 cerebral arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 claims 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- VMOJIHDTVZTGDO-UHFFFAOYSA-N Cadalene Chemical compound C1=C(C)C=C2C(C(C)C)=CC=C(C)C2=C1 VMOJIHDTVZTGDO-UHFFFAOYSA-N 0.000 claims 2
- 210000004556 brain Anatomy 0.000 abstract description 30
- 201000004810 Vascular dementia Diseases 0.000 abstract description 9
- 206010008118 cerebral infarction Diseases 0.000 abstract description 5
- 200000000007 Arterial disease Diseases 0.000 abstract description 3
- 210000004885 white matter Anatomy 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 102000001760 Notch3 Receptor Human genes 0.000 description 10
- 108010029756 Notch3 Receptor Proteins 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 102000005606 Activins Human genes 0.000 description 9
- 108010059616 Activins Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 239000000488 activin Substances 0.000 description 9
- 230000001717 pathogenic effect Effects 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 7
- UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 210000000877 corpus callosum Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 208000019695 Migraine disease Diseases 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 206010027599 migraine Diseases 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000002739 subcortical effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- LUWJPTVQOMUZLW-UHFFFAOYSA-N Luxol fast blue MBS Chemical compound [Cu++].Cc1ccccc1N\C(N)=N\c1ccccc1C.Cc1ccccc1N\C(N)=N\c1ccccc1C.OS(=O)(=O)c1cccc2c3nc(nc4nc([n-]c5[n-]c(nc6nc(n3)c3ccccc63)c3c(cccc53)S(O)(=O)=O)c3ccccc43)c12 LUWJPTVQOMUZLW-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 210000003668 pericyte Anatomy 0.000 description 4
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 210000003478 temporal lobe Anatomy 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000003934 vacuole Anatomy 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 206010072731 White matter lesion Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 229940127218 antiplatelet drug Drugs 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000002537 thrombolytic effect Effects 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 208000004552 Lacunar Stroke Diseases 0.000 description 2
- 208000034800 Leukoencephalopathies Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 238000010826 Nissl staining Methods 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 229960005370 atorvastatin Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229960003530 donepezil Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000002477 vacuolizing effect Effects 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000027647 Cerebral Cortical Thinning Diseases 0.000 description 1
- 206010067277 Cerebral microhaemorrhage Diseases 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 101000577202 Homo sapiens Neurogenic locus notch homolog protein 3 Proteins 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241001484259 Lacuna Species 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 206010063661 Vascular encephalopathy Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- 230000003942 amyloidogenic effect Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013176 antiplatelet therapy Methods 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000006736 behavioral deficit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 208000011142 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 Diseases 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 230000010456 cerebrovascular autoregulation Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000007577 cortical microinfarct Effects 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000002598 diffusion tensor imaging Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 206010049444 fibromatosis Diseases 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 208000022059 functional hyperemia Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000011686 genetic mapping animal model Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010060 microvascular dysfunction Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008529 pathological progression Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 208000022064 reactive hyperemia Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 102200063959 rs367543285 Human genes 0.000 description 1
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 description 1
- 229960004617 sapropterin Drugs 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940084026 sodium valproate Drugs 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 230000037436 splice-site mutation Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 229940124598 therapeutic candidate Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000010246 ultrastructural analysis Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Marine Sciences & Fisheries (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
Abstract
公开了用于降低CADASIL(脑常染色体显性遗传性动脉病合并皮质下梗死和白脑病)患者死亡率的脑活素。
Description
本发明涉及治疗CADASIL。
CADASIL(脑常染色体显性遗传性动脉病合并皮质下梗死和白脑病；或：CADASIL综合征)引起一种伴有遗忘的腔隙综合征，其主要特征包括复发性皮质下缺血事件和血管性痴呆，并且与神经影像学上的弥漫性白质异常有关。CADASIL以常染色体显性方式遗传。大多数受累个体都有一个受累父母。致病性从头变异似乎很少见。受累者的每个孩子都有50％的风险会继承致病性变异和发展出疾病迹象。如果已知家族有致病性变异，则可以对风险较高的妊娠进行产前检查，并进行植入前遗传学诊断；然而，针对典型的成人发病进行产前检查的申请并不常见。病理检查发现多发性小而深的脑梗死(cerebral infarcts)，白质脑病(leukoencephalopathy)和主要累及小脑动脉的非动脉粥样硬化、非淀粉样的血管病。血管平滑肌细胞的严重改变明显可见于超微结构分析中。该突变基因被定位到19号染色体，并在导致严重破坏该基因的CADASIL患者中鉴定出了人Notch3基因的多个突变。实际上，超过95％的CADASIL个体在Notch3中有致病性错义变异(Rutten et al.,in:Pagon etal.(Eds.)
(2000；updated 2016)；Seattle(WA):University ofWashington,Seattle；1993-2017；Joutel et al.,Nature 383(1996),707-710)。CADASIL患者中超过95％的Notch3突变是错义突变，而其他突变则是较小的框内缺失或剪接位点突变。令人惊讶的是，所有致病性突变都会导致给定的EGFR中存在奇数个半胱氨酸残基。据信半胱氨酸残基负责蛋白质的结构完整性，因此增加或丢失半胱氨酸残基可能损害正确的蛋白质折叠。从头突变很少见，但个别病例已有报道。
CADASIL的病理特征是，小动脉介质中有电子致密颗粒，且动脉壁的Notch3染色增强，这可在皮肤活检中评估。目前针对CADASIL尚无证实疗效的治疗方法。抗血小板治疗经常使用，但在CADASIL中尚未证明有效。偏头痛应根据发病频率进行对症地预防性治疗。高血压、糖尿病或高胆固醇血症的并发应予以治疗。支持性的护理(实践帮助，情感支持，和心理咨询)适用于受累个体及其家人。但是，建议避免使用可能引起脑血管意外的血管造影和抗凝剂等药物。还已知吸烟会增加缺血事件的风险。严禁溶栓治疗(静脉溶栓)，因为脑出血的风险可能会增加(Pagon et al.,2000；updated 2016)。
由于针对CADASIL尚无有效的治疗方法，因此，治疗旨在寻找可能的疾病缓解策略以减轻临床表现。但是，到目前为止，仅报道了一些非常初步的研究。
传闻有病例也使用丙戊酸钠进行偏头痛治疗。据报道，乙酰胆碱酯酶抑制剂在治疗认知功能减退的一级终点(18周后血管性痴呆评估量表)无效，但观察到额叶皮层下功能障碍的改善。已测试抗血小板药物对原发和继发中风的阻止效果；结果不确定，疗效有争议。还测试了乙酰唑胺使脑灌注增加的效果，是通过灌注MRI、经颅多普勒超声检查和Tc-99m胞外域脑灌注SPECT来评估。此外，它已被用作偏头痛的预防剂，目的是减少偏头痛发作的频率。对于阿托伐他汀(Atorvastatin)，经颅多普勒检查未见对脑血流有何影响。经颅多普勒检查发现，L-精氨酸表现出诱导型血管反应性。沙丙蝶呤(200-400mg，每日两次，24个月)的最终结果是，在一级终点(反应性充血指数的均差)，对外周血管反应性的任何改善均无显著意义。据报道，在小鼠模型中，干细胞因子和粒细胞集落刺激因子的组合限制了CADASIL的病理进展(综述见:Di Donato et al.,BMC Medicine(2017)15:41；DOI10.1186/s12916-017-0778-8)。
鉴于有证据表明，具有血管风险因子(尤其是吸烟和高血压)的患者病程更严重，故而控制血管风险因子被视为CADASIL管理的重要组成部分。关于抗血小板药物(如阿司匹林或氯吡格雷)的使用，大多数神经科医师在治疗CADASIL患者时均适用针对偶发性卒中的指南。但此法的适当性尚未确定。实际上，此病中的缺血性事件的血栓形成尚未得到证实。另一方面，许多报告都强调在相当大比例的CADASIL患者中存在微出血。由于这些原因，抗血小板药物在此病中的安全性尚待阐明。同样，溶血栓的益处尚不确定，尽管有人认为它对散发性腔隙性脑卒中有益。
在一项有168个病例的多奈哌齐(donepezil)多中心临床试验中，血管性痴呆评估量表的初步结局-认知子量表未有改善。但是，在几项执行功能(executive function)指标上已有改进，只是它们的临床相关性尚不清楚。CADASIL的并发症(例如抑郁症和偏头痛)似乎对与散发疾病中使用的类似疗法产生了反应(Di Donato et al.,2017)。Chen等人综述了用于血管性痴呆的脑活素(Cochrane Database of System.Rev.1(2013):DOI:10.1002/146 1858.CD008900.pub)。
在缺乏CADASIL的具体数据的情况下，大多数神经科医师对年龄较大的患者(例如40岁以上的患者)缺血性卒中后使用阿司匹林进行二级预防，但没有证据支持或反对使用阿司匹林。鉴于可能增加的出血风险，尚不确定该策略是否适用于CADASIL，尚需进一步研究。考虑到已报告的脑出血风险，应仔细随访有明确指症(例如高危房颤)而需要抗凝治疗的患者。
因此，很明显，需要针对CADASIL患者的新的合理治疗干预措施，以解决疾病症状和疾病进展，尤其是分别降低死亡率或提高生存率的治疗干预措施。
因此，本发明提供了脑活素(Cerebrolysin)，用于降低CADASIL(脑常染色体显性遗传性动脉病合并皮质下梗死和白脑病)患者的死亡率。
脑活素，一种通过脑蛋白的标准化酶促分解而制得的肽制剂，包括低分子量肽(<10kDa)和游离氨基酸。
脑活素是一种具有神经营养样特性的肽混合物，可消除临床前模型和痴呆症患者的行为和认知缺陷，并在卒中和TBI中改善运动功能、认知能力和日常生活活动。脑活素的作用方式是多营养的(pleiotrophic)，范围从神经保护特性(例如减少兴奋性毒性和自由基形成)到通过增加神经可塑性和神经发生而促进恢复。
脑活素已用于卒中和血管性痴呆。有报道称，对血管性痴呆患者的认知功能产生有益作用，可能是通过减少β-淀粉样蛋白沉积来实现。脑活素在欧洲和亚洲多个国家已获批用于治疗卒中。
通过本发明，令人惊讶地观察到脑活素对降低死亡率具有显著影响，因此对于提高CADASIL患者的存活率具有显著影响。尽管没有观察到对作为CADASIL标志的白质空泡化的影响(这使本发明更加令人惊讶)，但在现有的CADASIL小鼠模型中，脑活素治疗的死亡率具有统计学上非常显著的降低。
此效果是完全出乎意料的，特别是考虑到以下事实：在先前的出版物中，有报道称，脑活素在体外对来自CADASIL患者的细胞的氧化应激诱导型凋亡不具有保护作用(Formichi et al.,Neurol.Sci.34(2013),553-556；doi:10.1007/s10072-012-1174-y)。
在这项研究中，Formichi等人使用了来自15位CADASIL患者(年龄在34-70岁之间)的外周血淋巴细胞(PBL)和2-脱氧-D-核糖(dRib)，后者是高还原糖，用作促凋亡刺激物的范例。凋亡通过流式细胞术和荧光显微镜检来分析。对标准条件下培养的CADASIL患者PBL给予脑活素不影响凋亡细胞的百分比。对dRib培养的PBL给予Cere，导致培养48h后，仅5位患者的凋亡显著减少，而在其他10位患者中，脑活素治疗与凋亡百分比的任何显著差异无关。该结果表明，仅在30％的CADASIL患者中，脑活素对氧化应激诱导型凋亡具有保护作用。因此得出结论，Notch3基因在体外可能不影响脑活素的抗凋亡特性。这也可以解释在本发明的过程中获得的结果，即脑活素对空泡化没有作用。无论如何，脑活素可能对主要参数死亡率产生影响因此是完全出乎意料的。
不管Formichi等人所获得的结果，也不管CADASIL患者的Notch3基因有突变的事实，脑活素可以有效地用于治疗所有CADASIL患者，而获得本发明的效果。
CADASIL常常通过遗传学来诊断，优选对整个Notch3基因进行测序。多个位于NOTCH3外显子33(编码该蛋白的胞内部分的PEST结构域)中的杂合截短致病变体已在单侧脑膜综合征(雷曼综合征)中描述。推测这些致病变体通过获得Notch3信号传导功能而起作用，它们与CADASIL中的NOTCH3致病变体不同。一个Notch3外显子25致病变体(c.4556T>C,p.Leu1519Pro)已在常染色体显性婴儿性肌纤维瘤病中描述。
CADASIL患者的脑部磁共振成像(MRI)表现出T1加权图像上的低强度和T2加权图像上的高强度，通常是多种尺寸的融合性白质病变。这些病变集中在基底神经节、脑室周围白质和脑桥周围，且与Binswanger病中所见相似。这些白质病变在具有突变基因的无症状个体中也可见到。尽管MRI未用于诊断CADASIL，但它可以在症状发作的甚至数十年前就显示白质变化的进展。
CADASIL患者的白质变化常累及颞叶前部(anterior temporal lobe)、外囊(external capsule)和额上回(superior frontal gyrus)。颞叶前部的改变已显示出对该疾病具有高敏感性和特异性(每种情况约90％)，可用于诊断。在亚洲人群中，颞叶前部受累较少见。外囊改变也具有较高敏感度(大约90％)，但特异性较低(大约50％)。实际上，最近一项系统分析表明，外囊也类似地参与了CADASIL和散发的SVD。在散发的SVD中很少见到胼胝体信号异常在CADASIL有描述；这种异常也是多发性硬化的特征，这是将CADASIL误诊为多发性硬化的原因之一。经Gradient-回波成像显示有斑点样低信号病变的脑部微出血可见于各种比例的病例中(30～70％)，并且常随着年龄增长和诸如高血压之类的风险因子的增加而增加，脑出血也可见于不少患者，尤其是亚洲血统的患者(di Donato et al.,2017)。
CADASIL的ICD-10-CM诊断代码被归类为I67.8(“其他指定的脑血管疾病”)，且已被定义为皮质下疾病，但是最近对允许更高分辨率成像的高场7-Tesla MRI的研究检测到皮质的主要累及，包括确认皮质微梗死以及额叶和顶叶区的早期弥漫性皮质改变，其大都通常是在两个半球遵循对称模式。这些改变与皮质变薄或皮质下病变无关，有人假设其继发于静脉血管密度或髓内水肿。类似的数据也在实验模型中有报道。此外，皮质下改变可能诱发继发性皮质改变。在一项纵向研究中，偶发腔隙(incident lacunes)之后，皮层变薄，特别是在相连的大脑区域。最近的另一项研发是用扩散张量成像(diffusion tensorimaging)来表征组织损伤。在CADASIL患者中观察到的扩散指标的典型变化是分数各向异性(衡量扩散方向的指标)降低和表观扩散系数或平均扩散率(衡量扩散程度的指标)增加。直方图分析已被提议为一种可用于横向和纵向测量CADASIL相关变化的敏感工具(诊断和鉴别诊断参见di Donato等人，2017年和Rutten等人，2000年，更新于2016年)。
尽管仍被认为是诊断不足，但CADASIL诊断在过去20年中已显著改善，现在更加准确。
脑活素是经蛋白水解产生的来自于纯化的脑蛋白的神经肽的药物制剂。脑活素通常以标准化产品的形式在市场上出售。脑活素包含15％～30％的低分子量肽(<10kDa)和70～85％的游离氨基酸，例如丙氨酸，天冬氨酸，精氨酸，谷氨酸，甘氨酸，组氨酸，异亮氨酸，亮氨酸，赖氨酸，蛋氨酸，苯丙氨酸，脯氨酸，丝氨酸，苏氨酸，色氨酸，半胱氨酸和缬氨酸。溶液优选是无菌的，并且已准备好用于注射或输注(即，其满足将药物制剂施用于人类患者的所有标准和要求)。EP 0 452 299 A1 CN和Gromova等人(Difficult Patient 8(2010),25-31)公开了脑活素制剂。
根据本发明使用的优选的脑活素浓度在水溶液中每毫升包含50～1000mg，优选100～500mg，尤其是150～250mg脑活素浓缩物。如上所述，按总氮量计，脑活素包含约85％的游离氨基酸和15％的低分子量肽(<10kDa)。
脑活素浓缩物针对具体氨基酸有标准化含量。在浓缩物中(给药时，按所需，浓度可能会有所不同)，脑活素具有以下氨基酸含量(以mg/ml脑活素浓缩物计)：丙氨酸：2.40～3.60，尤其是3.10～3.50；天冬氨酸：2.40～3.60，尤其是2.20～3.50；缬氨酸：1.60～2.40，尤其是2.10～2.40；组氨酸：1.04～1.56，尤其是1.10～1.50；甘氨酸：1.20～1.80，尤其是1.60～1.90；谷氨酸：3.20-4.80，尤其是3.30-4.60；异亮氨酸：1.60～2.40，尤其是2.20～2.40；亮氨酸：4.80～7.20，尤其是5.70～6.30；赖氨酸：4.80～7.20，尤其是5.80～7.20；蛋氨酸：0.35～0.65，尤其是0.40～0.70；脯氨酸：1.60～2.40，尤其是2.00～2.40；丝氨酸：0.21～0.39，尤其是0.23～0.36；苏氨酸：0.21～0.39，尤其是0.26～0.35；色氨酸：0.35～0.65，尤其是0.40～0.70；苯丙氨酸：1.60～2.40，尤其是1.60～2.40。很明显，该浓缩物稀释后，每毫升中具体氨基酸的绝对量降低；然而，氨基酸彼此之间的比例以及相对于低分子量肽(10,000或更小)的比例经过稀释仍保持不变，这种相对比例是获得本发明疗效的基本要素。
在EP 0 452 299 A1中公开了一种生产脑活素的方法，是通过猪脑蛋白质组分的酶促水解获得的。每毫升该产品包含3.00mg丙氨酸，3.00mg天冬氨酸，0.06g胱氨酸，4.30mg谷氨酸，1.50mg甘氨酸，1.30mg组氨酸，2.00mg异亮氨酸，6.00mg亮氨酸，0.50mg蛋氨酸，2.00mg苯丙氨酸，2.00mg脯氨酸，0.30g丝氨酸，0.30g苏氨酸，0.50g色氨酸和2.00mg酪氨酸作为氨基酸以及分子量10.000以下的肽。在EP 0 452 299 A1中公开的制剂中，肽和氨基酸的混合物包含(对于典型的脑活素产品而言)约15％的分子量为10,000以下的肽和约85％的游离氨基酸。
所施加的剂量可优选在100～10000mg(0.5～50ml脑活素浓缩物)的范围内。优选地，CADASIL患者用0.1～100ml，优选1～50ml范围内的脑活素剂量治疗，相当于21.5～21,520mg脑活素浓缩物(优选的脑活素浓缩物包含215.2mg/ml)。如果是肌内施用，则剂量通常低于静脉内(例如，静脉内优选0.5～5ml，优选0.5～10ml)。因此，优选地，CADASIL患者用0.1～10ml，优选0.5～5ml的肌内给药剂量进行治疗，相当于21.5mg～2152mg脑活素浓缩物。脑活素也可以连续输注(通常以10ml以上的体积)，因此脑活素浓缩液可以例如用0.9％氯化钠溶液(9mg NaCl/ml)，林格氏液(Na+153.98mmol/l,Ca2+2,74mmol/l,K+4,02mmol/l,Cl-163,48mmol/l)，5％葡萄糖稀释。输注通常持续5分钟～4小时，优选10分钟～2小时，尤其是15～60分钟，(优选每天进行输注)，例如输注1～100天，优选5～50天，优选10～30天(通常地，仅在工作日给药，周末不给，因此一个治疗周期通常有3～5x 5个连续给药天数)。根据一优选实施方案，CADASIL患者用0.1～100ml、优选1～50ml的静脉内给药剂量来治疗，相当于215.2～21,520mg脑活素浓缩物。
可以在1～6个月、1～3个月、优选2～3个月的无治疗期之后重复治疗周期。
本发明用以下实施例和附图进一步说明，但不限于此。
图1显示了经计算的盐水处理组与脑活素组的小鼠死亡率(35％比0％)。
图2显示了CADASIL小鼠中线偏外0.5mm处矢状脑切面的luxol固蓝和Nissl染色。细胞体为深蓝；白质染成蓝绿。虚线包括观察到的区域，胼胝体前部(anterior corpuscallosum)。
图3显示了一只年轻健康小鼠(A)和一只18月龄CADASIL小鼠(B)中的胼胝体前部。六周龄雄性C57BL/6(A)的胼胝体(corpus callosum)前中部未见空泡化，而CADASIL小鼠(B)中明显空泡化。与圆形空泡相对照，可看到血管为细长结构(见内框)。
图4显示了18月龄CADASIL转基因小鼠在12～18个月期间用三轮载体(左)或脑活素(右)治疗后，胼胝体前部中的空泡数目。在这两组中，均观察到预期的病理，即白质的空泡化(两组之间无统计学显著性差异(p＝0.12；Student t-检验))。
实施例
脑活素在CADASIL小鼠模型中的疗效
材料和方法
CADASIL小鼠模型：NOTCH3R169C突变(品系88)
在表达NOTCH3R169C突变的现有转基因CADASIL小鼠模型(品系88)中进行概念验证研究，以检查脑活素在CADASIL中的疗效。外显子4中第169位残基从精氨酸变为半胱氨酸的这种特定取代已在CADASIL患者中报道，这似乎是一个频繁的突变(Joutel等，1997)。该转基因小鼠品系已在此前有详细表征来显示CADASIL的一些生化特征，因此被认为是适合该疾病的遗传动物模型(Ghosh等人，2015；Joutel等人，2010)。Joutel及其同事(Joutel等人，2010年)证明，这种小鼠体内突变的转基因的体内表达复制了内源性NOTCH3表达模式和CADASIL的主要病理特征，包括典型的NOTCH3ECD聚集物、脑血管中的GOM沉积、进行性白质损害和脑血流量减少。突变小鼠表现出肌原反应减弱，脑动脉内径缩小，以及脑血管自调节能力受损，功能性充血和白质毛细血管密度显著降低。最近一项对NOTCH3R169C模型的鉴定揭示了周细胞在脑血管功能失调和BBB渗漏中的重要作用，此作用引起CADASIL病理(Ghosh等人，2015)。这些作者表明，随着年龄增长，周细胞和平滑肌细胞周围聚集了突变的NOTCH3。NOTCH3积累引起细胞凋亡，导致周细胞数量显著减少，并且周细胞进展覆盖了毛细血管。这些变化与星形尾足脱离脑部微血管、BBB开放和微血管功能失调有关，指症表现为，血浆蛋白渗漏，内皮粘附连接蛋白的表达减少以及微血管对二氧化碳的反应性降低。
实验流程：
为了评估脑活素在该CADASIL小鼠模型中的作用，在启动三轮治疗周期之前，先对28只动物进行饲养并使其年龄超过12个月。给予突变小鼠2.5ml/kg用0.9％生理盐水稀释的脑活素或单独的生理盐水。随机全盲治疗以3周为一轮周期，每周5次IP注射(每只小鼠每次疗程共3x 15次注射)。动物分别在12、14和16月龄时治疗，在18月龄时处死以进行分析。这种治疗方案是基于在不同神经退行性疾病中测试脑活素疗效的实验研究中获得的数据而选出的。启动治疗前允许12个月的生长过程是源于以下发现：该模型的小鼠在此月龄左右开始显出CADASIL的典型疾病特征(Joutel等，2010)。
此外，考虑到药物实际应用转化，选择了治疗性而非预防性干预方法来代表现实的临床情况，一旦病理学发展到可以诊断的阶段，治疗便会开始。死亡率被选为主要参数，它代表了可靠且临床有效的结果指标。另外，CADASIL特异性白质病变的范围通过用luxol固蓝染色进行的组织学分析来定量。为此，对动物进行灌注，将脑部包埋在石蜡中。每只动物检查胼胝体前中部三个矢状切面的两个计数区域。
结果
脑活素治疗完全预防了CADASIL转基因小鼠的死亡。在12到18个月的观察期内(对应动物年龄)，对照组的14只小鼠中有5只死亡(36％)，但是脑活素治疗组中没有一只动物死亡。盐水治疗组的计算死亡率为35％，而脑活素组为0％，表明脑活素疗法在该疾病中具有促进存活的作用(图1)。
然后通过灌注固定杀死动物，取出大脑，包埋在石蜡中，矢状切开，并用luxol固蓝染色以测试白质中的空泡化。图2显示了CADASIL小鼠中线外侧0.5mm处矢状脑切面的luxol固蓝和Nissl染色。细胞体为深蓝色；白质染成蓝绿色。虚线包括观察到的区域，胼胝体前部。
六周龄雄性C57BL/6在胼胝体前中部未见空泡化(图3A)，已知胼胝体前中部在CADASIL小鼠中发生了病理改变(Joutel et al,J.Clin.Invest.120(2010),433-445)。相反，在CADASIL小鼠中观察到明显的空泡化(图3B)。因此，有可能再现文献中已知的CADASIL小鼠的白质的病理变化。在用载体物质治疗的动物中，测出了22±7个空泡(平均值±标准偏差，n＝8)，在用脑活素治疗的动物中测出了26±5个空泡(n＝14)。组间差异不显著(图4；p＝0.12；Student t检验)。在这方面，脑活素看来对CADASIL小鼠的白质空泡化无效。
综上，对死亡率的突出积极作用表明，脑活素是对抗CADASIL疾病的有效治疗剂候选物。
Claims (12)
1.用于降低CADASIL患者死亡率的脑活素。
2.根据权利要求1所述而用的脑活素，其中所述CADASIL患者在Notch3基因中具有突变。
3.根据权利要求1或2所述而用的脑活素，其中所述CADASIL患者用脑活素制剂治疗，所述脑活素制剂在每ml水溶液中含有50～1000mg、优选100～500mg、尤其是150～250mg脑活素浓缩物。
4.根据权利要求1至3中任一项所述而用的脑活素，其中所述CADASIL患者以0.1～100ml、优选1～50ml的脑活素剂量进行治疗，这相当于21.5～21,520mg脑活素浓缩物。
5.根据权利要求1至4中任一项所述而用的脑活素，其中所述CADASIL患者以0.1～10ml、优选0.5～5ml的肌内给药剂量进行治疗，这相当于21.5mg～2152mg脑活素浓缩物。
6.根据权利要求1至4中任一项所述而用的脑活素，其中所述CADASIL患者用0.1～100ml、优选1～50ml的静脉内给药剂量进行治疗，这相当于215.2～21,520mg脑活素浓缩物。
7.根据权利要求1至6中任一项所述而用的脑活素，其中所述CADASIL患者通过连续输注脑活素来治疗。
8.根据权利要求7所述而用的脑活素，其中以5分钟至4小时，优选10分钟至2小时，特别是15至60分钟的输注持续时间来进行输注；和/或其中输注进行1至100天，优选5至50天，特别是10至30天。
9.根据权利要求8所述而用的脑活素，其中输注每天进行一次。
10.根据权利要求1至9中任一项所述而用的脑活素，其中脑活素通过用0.9％氯化钠溶液、林格氏溶液或5％葡萄糖稀释来进行输注。
11.根据权利要求1至10中任一项所述而用的脑活素，其中所述CADASIL患者用含有氢氧化钠的脑活素制剂治疗。
12.根据权利要求1至11中任一项所述而用的脑活素，其中所述CADASIL患者以治疗周期进行治疗，所述治疗周期在1至6、优选1至3、特别是2至3个月的无治疗期之后重复。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17188180.8 | 2017-08-28 | ||
| EP17188180.8A EP3449931B1 (en) | 2017-08-28 | 2017-08-28 | Use of cerebrolysin |
| PCT/EP2018/073106 WO2019042983A1 (en) | 2017-08-28 | 2018-08-28 | USE OF CERBROLYSINE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111050780A true CN111050780A (zh) | 2020-04-21 |
| CN111050780B CN111050780B (zh) | 2023-11-03 |
Family
ID=59745228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880055542.5A Active CN111050780B (zh) | 2017-08-28 | 2018-08-28 | 脑活素的用途 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200376040A1 (zh) |
| EP (2) | EP3449931B1 (zh) |
| JP (1) | JP7281450B2 (zh) |
| KR (1) | KR20200045503A (zh) |
| CN (1) | CN111050780B (zh) |
| AU (1) | AU2018326339A1 (zh) |
| CA (1) | CA3073991A1 (zh) |
| EA (1) | EA202090108A1 (zh) |
| ES (2) | ES2767070T3 (zh) |
| HR (1) | HRP20200031T1 (zh) |
| MX (1) | MX2020002267A (zh) |
| PH (1) | PH12020500376A1 (zh) |
| PL (2) | PL3449931T3 (zh) |
| WO (1) | WO2019042983A1 (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020198037A1 (en) * | 2019-03-25 | 2020-10-01 | The University Of Vermont | Methods to promote cerebral blood flow in the brain |
| ES2964145T3 (es) | 2020-07-13 | 2024-04-04 | Ever Neuro Pharma Gmbh | Método para producir un hidrolizado de proteína de cerebro de mamífero |
| JP2024521224A (ja) * | 2021-06-02 | 2024-05-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 神経原性座位Ｎｏｔｃｈホモログタンパク質３（ＮＯＴＣＨ３）剤による脳血管疾患の治療 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69126563T2 (de) | 1990-04-12 | 1998-02-05 | Ebewe Arzneimittel | Verwendung einer Mischung von Peptiden and Aminosäuren für die Prophylaxis oder Behandlung von Dementia |
| RU2483713C2 (ru) | 2008-08-20 | 2013-06-10 | Борд Оф Риджентс, Зе Юниверсити Оф Техас Систем | Экструзия горячего расплава множественных частиц модифицированного высвобождения |
-
2017
- 2017-08-28 PL PL17188180T patent/PL3449931T3/pl unknown
- 2017-08-28 EP EP17188180.8A patent/EP3449931B1/en active Active
- 2017-08-28 ES ES17188180T patent/ES2767070T3/es active Active
-
2018
- 2018-08-28 PL PL18759322T patent/PL3675879T3/pl unknown
- 2018-08-28 EP EP18759322.3A patent/EP3675879B1/en active Active
- 2018-08-28 KR KR1020207007069A patent/KR20200045503A/ko active IP Right Grant
- 2018-08-28 WO PCT/EP2018/073106 patent/WO2019042983A1/en unknown
- 2018-08-28 US US16/642,307 patent/US20200376040A1/en active Pending
- 2018-08-28 ES ES18759322T patent/ES2901508T3/es active Active
- 2018-08-28 CN CN201880055542.5A patent/CN111050780B/zh active Active
- 2018-08-28 CA CA3073991A patent/CA3073991A1/en active Pending
- 2018-08-28 MX MX2020002267A patent/MX2020002267A/es unknown
- 2018-08-28 JP JP2020512835A patent/JP7281450B2/ja active Active
- 2018-08-28 EA EA202090108A patent/EA202090108A1/ru unknown
- 2018-08-28 AU AU2018326339A patent/AU2018326339A1/en active Pending
-
2020
- 2020-01-09 HR HRP20200031TT patent/HRP20200031T1/hr unknown
- 2020-02-26 PH PH12020500376A patent/PH12020500376A1/en unknown
Non-Patent Citations (3)
| Title |
|---|
| ILARIA DI DONATO ET AL: "Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) as a model of small vessel disease: update on clinical, diagnostic, and management aspects" * |
| NING CHEN ET AL: "Cerebrolysin for vascular dementia" * |
| PATRIZIA FORMICHI ET AL: "Effects of cerebrolysin administration on oxidative stress-induced apoptosis in lymphocytes from CADASIL patients" * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3073991A1 (en) | 2019-03-07 |
| AU2018326339A1 (en) | 2020-03-05 |
| MX2020002267A (es) | 2020-10-22 |
| KR20200045503A (ko) | 2020-05-04 |
| PL3449931T3 (pl) | 2020-06-01 |
| HRP20200031T1 (hr) | 2020-03-20 |
| ES2901508T3 (es) | 2022-03-22 |
| PH12020500376A1 (en) | 2020-12-07 |
| CN111050780B (zh) | 2023-11-03 |
| JP2020531568A (ja) | 2020-11-05 |
| JP7281450B2 (ja) | 2023-05-25 |
| US20200376040A1 (en) | 2020-12-03 |
| EP3675879A1 (en) | 2020-07-08 |
| PL3675879T3 (pl) | 2022-02-14 |
| ES2767070T3 (es) | 2020-06-16 |
| EP3675879B1 (en) | 2021-09-15 |
| EA202090108A1 (ru) | 2020-03-31 |
| WO2019042983A1 (en) | 2019-03-07 |
| EP3449931A1 (en) | 2019-03-06 |
| EP3449931B1 (en) | 2019-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sheng et al. | Sildenafil improves vascular and metabolic function in patients with Alzheimer’s disease | |
| US10240156B2 (en) | Modulation of synaptic maintenance | |
| CN111050780A (zh) | 脑活素的用途 | |
| JP2000507828A (ja) | アルツハイマー病の診断および治療法 | |
| Wang et al. | Tumor necrosis factor receptor‐associated factor 5 is an essential mediator of ischemic brain infarction | |
| KR20180004158A (ko) | Tpp1 제제 및 cln2 질환의 치료 방법 | |
| Ratilal et al. | Neuroprotective effects of erythropoietin pretreatment in a rodent model of transient middle cerebral artery occlusion | |
| CN108472332B (zh) | 用于通过经鼻施用来治疗中风的组合物 | |
| Walberer et al. | RNase therapy assessed by magnetic resonance imaging reduces cerebral edema and infarction size in acute stroke | |
| Ibarra et al. | Copolymer-1 (Cop-1) improves neurological recovery after middle cerebral artery occlusion in rats | |
| US20120225051A1 (en) | Tissue kallikrein for the treatment of huntington's disease | |
| Briones et al. | Environmental experience modulates ischemia-induced amyloidogenesis and enhances functional recovery | |
| BR112020000115A2 (pt) | sais farmaceuticamente aceitáveis de polipeptídeos e uso dos mesmos | |
| EA040978B1 (ru) | Применение церебролизина | |
| Zhang et al. | Cholecystokinin B Receptor Agonists Alleviates Anterograde Amnesia in CCK-deficient and Aged Alzheimer's Disease Mice | |
| Zhang et al. | Astragaloside IV protects against autoimmune myasthenia gravis in rats via regulation of mitophagy and apoptosis | |
| US20200289473A1 (en) | Methods of treating neurodegeneration | |
| HRP20220370A1 (hr) | Postupci liječenja cln2 bolesti kod pedijatrijskih subjekata | |
| Martins | Modulation of Retinal Ganglion Cell Function and Implications for Neuroprotection | |
| Allenbach et al. | P. 14.11 Auto-immune necrotizing myopathies with anti-HMGCR antibodies are related to statin-exposure only for a minority of cases | |
| US20040092439A1 (en) | Migraine and vasodilation treatment | |
| Galvão | Evaluation of the potential protective effects of adenosine A3 receptor in retinal ganglion cell degeneration | |
| Clarke et al. | MTHFR and Carotid Atheroscierosis With Smoking | |
| Yu | Effects of ghrelin on doxorubicin-induced toxicity in skeletal muscle |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |